In a powerful move for healthcare and technology, American Heart Association (AHA) Ventures has partnered with MDisrupt, a pioneering platform offering AI-powered access to healthcare experts. AHA Ventures, the newly created venture arm of the American Heart Association, has invested $1 million into MDisrupt, a platform that connects healthcare and life sciences companies with curated, specialized experts essential for navigating today’s challenging health tech landscape. This investment not only signifies AHA’s commitment to advancing health tech but also promises new avenues for evidence-based innovations to flourish.
The collaboration goes beyond funding; it represents a joint mission to make healthcare products and solutions more accessible and validated by science. As part of this deal, Lisa Suennen, managing partner of AHA Ventures and a healthcare industry veteran, has joined MDisrupt’s board. Suennen brings extensive experience in health innovation, aiming to amplify MDisrupt’s reach and help shape the next generation of healthcare technology.
A Transformative Platform Built to Address Real-World Health Tech Challenges
MDisrupt’s AI-powered Health Expert Marketplace has gained attention for its novel approach to addressing a significant issue within the health tech industry: the lack of access to expert advice that early-stage companies need to navigate clinical validation, regulatory hurdles, and commercialization.
While innovation in health tech is booming, the risks for startups are high—nearly 98% of digital health startups fail, often due to insufficient regulatory expertise, market strategy, or clinical rigor. In fact, the rapid evolution of technology means that healthcare innovators must meet strict regulatory and clinical requirements, making expert guidance indispensable.
At the heart of MDisrupt’s platform is a precision AI matching algorithm that enables health tech companies to connect with over 2,500 highly vetted professionals, from clinicians to commercial and regulatory specialists. This precision in expert matching is not only essential for early development but also for market longevity. The need for such a platform is further underscored by the daunting health app landscape, where roughly 53% of health apps are uninstalled within a month due to issues like poor user experience or lack of clinical validation.
Ruby Gadelrab, CEO of MDisrupt, emphasizes the platform’s unique role in healthcare innovation, explaining, “Our mission is to bring evidence-based, impactful healthcare products to market faster, supported by the right expertise.” Through this collaboration with AHA Ventures, MDisrupt aims to expand its reach even further, integrating the expertise of AHA’s vast network of health professionals to serve as consultants and advisors. This will create new pathways for AHA members to actively shape health solutions and elevate standards in patient care.
A Unique Collaboration with a Dual Mission
What sets this collaboration apart is the dual mission it fulfills for both organizations. For AHA Ventures, the investment aligns with their goal of promoting long-term health and well-being through evidence-based solutions. For MDisrupt, the partnership provides access to one of the world’s largest networks of cardiovascular and brain health professionals. This collaboration enables AHA members to apply their expertise in new roles, shaping technologies that directly impact patient care and outcomes.
In discussing the collaboration, Suennen explained that AHA was drawn to MDisrupt’s willingness to co-develop and refine its product based on AHA’s feedback. Unlike large companies that may be less open to collaboration, MDisrupt, a younger company, offers flexibility and adaptability.
This partnership represents an opportunity for AHA Ventures to influence health tech products in ways that align closely with AHA’s mission and standards. Suennen stated, “We’re not just investing; we’re partnering in this endeavor to ensure our members’ impressive knowledge impacts health solutions that are both scientifically validated and evidence-based”.
For MDisrupt, this relationship goes beyond traditional funding. The collaboration will enable MDisrupt to integrate AHA’s expert members into the platform, strengthening its offerings in fields like cardiovascular health, where AHA’s expertise is unrivaled. This integration will ensure that health tech products can be guided by experts who understand the clinical landscape, paving the way for solutions that are both effective and patient-centered.
AI in Healthcare Innovation: Why Expert Access Matters
The role of AI in health tech innovation is expanding rapidly, with projections estimating the AI health tech market could reach $67.4 billion by 2027. The AI revolution in healthcare not only accelerates innovation but also demands regulatory and clinical input at each stage of product development. Through MDisrupt’s marketplace, companies can access expert guidance on navigating the often complex regulatory landscape, from early product design to post-market strategies like reimbursement and user adoption.
This AI-powered approach is particularly relevant in a market where fast, reliable expert input can make or break a product. Health tech innovators face significant challenges, including an increasingly crowded digital health landscape and a rigorous approval process for new technologies. Without access to domain-specific expertise, companies are at risk of facing regulatory setbacks or failing to generate the evidence needed to support market entry.
MDisrupt’s platform addresses this issue by providing targeted expertise exactly when it’s needed, from compliance requirements to clinical insights, enabling products to reach the market both faster and more responsibly.
Gadelrab highlighted that too many promising startups struggle not due to a lack of innovation but because they can’t access the specialized healthcare expertise they need. Whether it’s understanding complex regulations, engaging with health systems, or developing clinical evidence, these companies need guidance that general platforms can’t provide. MDisrupt fills this gap, ensuring that health tech products are developed with a clear path to success.
Building on AHA’s Legacy of Health Innovation
AHA Ventures’ investment in MDisrupt is an extension of the Association’s long-standing commitment to health innovation. For over a century, AHA has championed cardiovascular health and been at the forefront of scientific advancements. This partnership allows AHA Ventures to further their mission by investing in platforms that prioritize evidence-based, high-quality healthcare solutions.
Suennen notes that “Through our collaboration with MDisrupt, we’re creating a healthcare ecosystem that brings together the best minds in science and technology to improve patient outcomes and promote healthier lives”.
By making MDisrupt’s platform accessible to its members, AHA Ventures is enabling a new form of engagement for healthcare professionals. Members now have the opportunity to contribute to health tech innovations in a way that reflects AHA’s commitment to quality and equity in healthcare. This not only extends AHA’s influence but also gives members a platform to shape technologies that will drive the future of patient care and health outcomes.
The Future of Health Tech: AHA and MDisrupt’s Vision for 2025 and Beyond
Looking to the future, the partnership between AHA and MDisrupt is poised to bring about transformative changes in health tech innovation. By mid-2025, MDisrupt plans to roll out extended offerings on its platform, allowing AHA’s professional members to engage with a wider array of health tech and life sciences sectors. This phase of development is expected to include new features tailored specifically to the needs of AHA’s members, creating pathways for experts to engage with companies as consultants, advisors, or even fractional team members.
Additionally, this collaboration signals a shift towards evidence-based, clinically validated health tech solutions. By integrating AHA members’ expertise into MDisrupt’s platform, the companies are setting a new standard for responsible innovation, ensuring that products are not only innovative but also meet the highest standards of clinical relevance and regulatory compliance.
The projected impact is significant: with MDisrupt’s support, the next generation of health tech and medtech products will be more integrated into clinical workflows, grounded in evidence, and capable of demonstrating real-world impact on patient outcomes.
The Importance of Partnerships in Navigating the Future of Healthcare
In today’s healthcare landscape, strategic partnerships like the one between AHA Ventures and MDisrupt play an essential role in fostering innovation while ensuring patient safety and clinical effectiveness. As health tech continues to evolve, the industry will increasingly rely on platforms that can provide the right expertise at the right time. MDisrupt’s focus on curated, healthcare-specific expertise and AHA Ventures’ commitment to evidence-based health solutions make this partnership a model for future collaborations.
Together, AHA and MDisrupt are not only addressing the needs of health tech companies but also elevating the standards for what these technologies can achieve. With the right support, health tech solutions can overcome the high failure rates that currently plague the industry, setting a foundation for products that are both innovative and clinically sound. This collaboration has the potential to reshape how healthcare professionals engage with industry, creating a more sustainable and impactful future for health innovation.
Are you interested in how AI is changing healthcare? Subscribe to our newsletter, “PulsePoint,” for updates, insights, and trends on AI innovations in healthcare.
